secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-07-08T12:00:09+00:00
Accession:  0001193125-26-298005
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres reports 80% immunosuppressive-free clinical response for SER-155 in irEC trial
--------------------------------------------------------------------------------

- 12 of 15 patients (80%) achieved primary endpoint: ≥1-grade diarrhea improvement without immunosuppressives at Day 15.
- 5 of 15 (33%) achieved complete remission (Grade 0 diarrhea) at Day 15; 2 of 15 (13%) maintained at Day 43.
- SER-155 well tolerated; no drug-related serious adverse events or bloodstream infections through Day 43.
- Biomarkers (fecal calprotectin, albumin) showed statistically significant reductions at Day 43, indicating reduced GI inflammation.
- Company engaging with potential partners for SER-155 development in irEC and seeking funding for allo-HCT Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/0001193125-26-298005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/d130829d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-298005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer